Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.53 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.47 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.47 |
| ▸ | TK2 | O00142 | 2/20 | 0.46 |
| ▸ | CDA | P32320 | 7/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2056570 | 0.84 | SLC28A1 (0.47) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL27804325 | 0.83 | SLC28A1 (0.46) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL8538141 | 0.83 | PYGM (0.46) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL15689564 | 0.83 | PYGM (0.46) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL8536800 | 0.83 | PYGM (0.46) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL8536802 | 0.83 | PYGM (0.46) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL27773751 | 0.82 | TK2 (0.60) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL8333791 | 0.82 | TK2 (0.60) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL6753689 | 0.82 | TK2 (0.60) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL6753655 | 0.79 | SLC28A1 (0.53) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025080839-A1 | IMPROVED RADIOSYNTHESIS OF 18F-LABELED NUCLEOSIDE ANALOGUES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2025-04-17 | — | — | WO | claimed |
| US-20230416293-A1 | SYNTHESIS OF [18F]-LABELED THYMIDINE ANALOGUES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-12-28 | — | — | US | claimed |
| US-20230416293-A1 | SYNTHESIS OF [18F]-LABELED THYMIDINE ANALOGUES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-12-28 | — | — | US | disclosed |
| CN-1678326-A | 2 '-C-methyl-3' -O-L-valine ester ribofuranosyl cytidine for treatment of flavivirus infections | IDENIX CAYMAN LTD (KY) | 2005-10-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416293-A1 | SYNTHESIS OF [18F]-LABELED THYMIDINE ANALOGUES | DCTD, DUT, RNMT | PYGM 3840/4885SLC28A1 33/4885SLC28A2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.